Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE: Ivospemin with Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT05254171Phase 3Recruiting
- Sponsor
- Panbela Therapeutics
- Start
- Aug 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of ivospemin in pancreatic adenocarcinoma (PDAC), sponsored by Panbela Therapeutics. Started Aug 2022; status: recruiting.
02
Drugs
ivospemin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05254171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254171.